EUVIMEDEUVIMED entdecken
Crossref

Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway

Xiangxiang Wei, Jiayu Jin, Jian Wu, Yunquan He, Jieyu Guo, Zhaohua Yang, Liang Chen, Kui Hu, Liliang Li, Mengping Jia, Qinhan Li, Xiaoyu Lv und 9 weitere

Cardiovascular Research · 2023

DOI: 10.1093/cvr/cvad086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2023. Verfasst von Xiangxiang Wei und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Department of Rheumatology, Zhongshan Hospital, Fudan University, 138…. Hauptthemen laut MEDLINE: Calcium-Calmodulin-Dependent Protein Kinase Type 2, Calcium. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Commission of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

BACH1 is up-regulated in hypertrophic hearts, but its function in cardiac hypertrophy remains largely unknown. This research investigates the function and mechanisms of BACH1 in the regulation of cardiac hypertrophy. Methods and results Male cardiac-specific BACH1 knockout mice or cardiac-specific BACH1 transgenic (BACH1-Tg) mice and their respective wild-type littermates developed cardiac hypertrophy induced by angiotensin II (Ang II) or transverse aortic constriction (TAC). Cardiac-specific BACH1 knockout in mice protected the hearts against Ang II- and TAC-induced cardiac hypertrophy and fibrosis, and preserved cardiac function. Conversely, cardiac-specific BACH1 overexpression markedly exaggerated cardiac hypertrophy and fibrosis and reduced cardiac function in mice with Ang II- and TAC-induced hypertrophy. Mechanistically, BACH1 silencing attenuated Ang II- and norepinephrine-stimulated calcium/calmodulin-dependent protein kinase II (CaMKII) signalling, the expression of hypertrophic genes, and hypertrophic growth of cardiomyocytes. Ang II stimulation promoted the nuclear localization of BACH1, facilitated the recruitment of BACH1 to the Ang II type 1 receptor (AT1R) gene promoter, and then increased the expression of AT1R. Inhibition of BACH1 attenuated Ang II-stimulated AT1R expression, cytosolic Ca2+ levels, and CaMKII activation in cardiomyocytes, whereas overexpression of BACH1 led to the opposite effects. The increased expression of hypertrophic genes induced by BACH1 overexpression upon Ang II stimulation was suppressed by CaMKII inhibitor KN93. The AT1R antagonist, losartan, significantly attenuated BACH1-mediated CaMKII activation and cardiomyocyte hypertrophy under Ang II stimulation in vitro. Similarly, Ang II-induced myocardial pathological hypertrophy, cardiac fibrosis, and dysfunction in BACH1-Tg mice were blunted by treatment with losartan.

Conclusion

This study elucidates a novel important role of BACH1 in pathological cardiac hypertrophy by regulating the AT1R expression and the Ca2+/CaMKII pathway, and highlights potential therapeutic target in pathological cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium-Calmodulin-Dependent Protein Kinase Type 2CalciumMiceMaleAnimalsLosartanCardiomegalyMyocytes, CardiacMice, TransgenicAngiotensin IIMice, KnockoutFibrosisMice, Inbred C57BL

Stichwörter der Autor:innen

Angiotensin II type 1 receptorBACH1CaMKIICardiac hypertrophyCardiac myocyte

Substanzen

Calcium-Calmodulin-Dependent Protein Kinase Type 2CalciumLosartanAngiotensin II

Autor:innen und Institutionen

  • Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Department of Rheumatology, Zhongshan Hospital, Fudan University, 138 Yixueyuan Road, Xuhui District, Shanghai 200032, China.
  • Shanghai Medical College and Zhongshan Hospital Immunotherapy Translational Research Center, 446 Zhaojiabang Road, Xuhui District, Shanghai 200032, China.
  • Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, 180 Fenglin Road, Xuhui District, Shanghai 200032, China.
  • Department of Cardiovascular Surgery, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Xuhui District, Shanghai 200032, China.
  • State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences, 167 Beilishi Road, Xicheng District, Beijing 100037, China.
  • Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, 83 Zhongshan East Road, Nanming District, Guizhou 550499, China.

ORCID-Profile: Lindi Jiang, Elena Osto, Dan Meng

Förderung

  • National Natural Science Foundation of China
  • Shanghai Science and Technology Commission of China
  • National Key Research and Development Program of China
  • Fudan University

Zitieren

APA

Wei, X., Jin, J., Wu, J., He, Y., Guo, J., Yang, Z., Chen, L., Hu, K., Li, L., Jia, M., Li, Q., Lv, X., Ge, F., Ma, S., Wu, H., Zhi, X., Wang, X., Jiang, L., Osto, E., …, & Meng, D. (2023). Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad086

Vancouver

Wei X, Jin J, Wu J, He Y, Guo J, Yang Z, et al. Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway. Cardiovascular Research. 2023. doi:10.1093/cvr/cvad086

BibTeX
@article{Wei2023,
  author = {Wei, Xiangxiang and Jin, Jiayu and Wu, Jian and He, Yunquan and Guo, Jieyu and Yang, Zhaohua and Chen, Liang and Hu, Kui and Li, Liliang and Jia, Mengping and Li, Qinhan and Lv, Xiaoyu and Ge, Fei and Ma, Siyu and Wu, Huijie and Zhi, Xiuling and Wang, Xinhong and Jiang, Lindi and Osto, Elena and Zhang, Jianyi and Meng, Dan},
  title = {Cardiac-specific BACH1 ablation attenuates pathological cardiac hypertrophy by inhibiting the Ang II type 1 receptor expression and the Ca2+/CaMKII pathway},
  journal = {Cardiovascular Research},
  year = {2023},
  doi = {10.1093/cvr/cvad086}
}
Kostenlos starten →